Clinical trials: Impairment
Macular Edema
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
This is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision…
- Trial name
- NCT02732951
- Testing
- BI 1026706
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Hepatic Impairment
Pharmacokinetics of BAF312 in Patients With Hepatic Impairment
This study will investigate the pharmacokinetics of BAF312 in patients with mild, moderate and severe hepatic impairment compared to healthy control subjects.
- Trial name
- NCT01565902
- Testing
- BAF312
- Where
- 3 sites in Hungary, Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Dementia
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.
- Trial name
- NCT01059877
- Testing
- 1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Quietmind Foundation
Mild Cognitive Impairment
Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment
Computerized cognitive interventions (CCIs) have been increasingly widely implemented among older adults with mild cognitive impairment (MCI).
- Trial name
- CogT-PACT (NCT03292705)
- Testing
- PEP, CCI
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Mild Cognitive Impairment (MCI), Alzheimer Disease
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT05108922
- Testing
- Donanemab, Aducanumab
- Where
- 31 sites in United States
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Disease
A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
The purpose of this study is to measure how much of the study drug, evacetrapib, enters the blood stream and how long it takes the body to dispose of the study drug when given to participants with severe renal (kidney) impairment…
- Trial name
- NCT01825889
- Testing
- Evacetrapib
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated…
- Trial name
- NCT01068860
- Testing
- Canakinumab 150 mg
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Novartis
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
This 2-part, open-label study was designed to investigate the safety, tolerability, and efficacy of [18F]MK-6240, a Positron Emission Tomography (PET) imaging agent, for the quantification of neurofibrillary tangle (NFT)…
- Trial name
- NCT02562989
- Testing
- [18F]MK-6240, ~185 MBq, [18F]MK-6240, ~160 MBq
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cognition Disorder, Stroke
NeuroCognition After Carotid Recanalization
Complete occlusion of the Internal carotid artery (ICA) by atherosclerotic disease (COICA) causes approximately 15%-25% of ischemic strokes in the carotid artery distribution.
- Conditions
- Cognition Disorder, Stroke, Occlusion Carotid
- Trial name
- NIA-SCORE (NCT04219774)
- Testing
- Endovascular intervention, Aspirin and Clopidogrel (maximal medical Therapy)
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Renal Insufficiency, Healthy
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.
- Trial name
- NCT03302091
- Testing
- BI 1467335
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cardiomyopathy, Renal Impairment
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral response to acute sodium loading in subjects…
- Trial name
- Aim2 (NCT01970176)
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Hepatic Impairment
Study of Nalbuphine ER in Participants With Hepatic Impairment
This research study will evaluate the effect of hepatic impairment on the pharmacokinetics (the breakdown of the drug in the body) of parallel-group, multiple oral doses nalbuphine extended release (NAL ER), tablets in people…
- Trial name
- NCT04020016
- Testing
- Nalbuphine ER
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Trevi Therapeutics
Type 2 Diabetes Mellitus
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction.
- Trial name
- NCT02964585
- Testing
- Canagliflozin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- George Washington University
Impaired Fasting Glucose, Prediabetes
Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
The objective of this study is to determine the effect of 8 weeks of treatment with colesevelam HCl 3.75 g once daily with the evening meal on ß-cell function by evaluating the acute insulin response (AIRg) to an intravenous…
- Trial name
- NCT00990184
- Testing
- Colesevelam
- Volunteers
- 21 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Posttraumatic Stress Disorder, Depression
A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot
The goal of this pilot study is to develop and implement a larger scale, multi-site stepped collaborative care trial that targets injured patients with presentations of posttraumatic stress disorder (PTSD) and related…
- Conditions
- Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation
- Trial name
- TSOS6 (NCT02335125)
- Testing
- Motivational Interviewing, Cognitive Behavioral Therapy Elements, Psychotropic Drugs
- Volunteers
- 40 people
- Sponsor
- University of Washington
Insulin Resistance, Obesity
Metformin Effect on Brain Function in Insulin Resistant Elderly People
Alzheimer's disease (AD) and other forms of dementia are rapidly increasing with the aging of the population, and show a clear preponderance among people with insulin resistance.
- Conditions
- Insulin Resistance, Obesity, Obesity, Abdominal
- Trial name
- NCT03733132
- Testing
- Metformin Hydrochloride
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Dementia, Alzheimer's Disease
Indiana University Dementia Screening Trial
The purpose of the study is to conduct a randomized clinical trial assessing the harms and benefits of screening for dementia, compared to no screening for dementia, among 4,000 older adults, cared for in typical, primary care…
- Conditions
- Dementia, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- IU-CHOICE (NCT01699503)
- Testing
- Collaborative Dementia Care Program
- Where
- 3 sites in United States
- Volunteers
- 4,005 people
- Sponsor
- Indiana University
Type 2 Diabetes Mellitus, Renal Impairment
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
The TRENT trial is designed to confirm the efficacy and safety of Gla-300 compared with IDeg-100 in insulin-naïve patient (participants who have not tried insulin) with Type 2 Diabetes Mellitus (T2DM) and renal impairment.
- Trial name
- TRENT (NCT05552859)
- Testing
- Insulin glargine 300 U/mL, Insulin degludec 100 U/mL
- Where
- 68 sites in United States, Czechia and 3 more
- Volunteers
- 62 people
- Sponsor
- Sanofi
Hepatic Impairment
Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment
Phase 1, multicenter, open-label, 2-part, single- and multiple-dose study designed to assess the effect of hepatic insufficiency on the PK of aramchol
- Trial name
- NCT04480827
- Testing
- Aramchol free acid tablet 600mg, single dose, Aramchol free acid tablet 300mg, bid
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Galmed Research and Development, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.